• Policy
• Gov't 'Too soon to price immune-oncology drugs by indication
• by Lee, Jeong-Hwan Feb 22, 2024 05:49am

• Policy
• ‘Gavreto’ withdrawn from KOR amid reimb rejection
• by Lee, Hye-Kyung Feb 21, 2024 05:45am

• Policy
• President Yoon asks doctors to 'stop collective action'
• by Lee, Jeong-Hwan Feb 21, 2024 05:45am

• Policy
• Multiple low-dose Kerendia Rx subject to reimb cuts
• by Lee, Tak-Sun Feb 20, 2024 06:00am

• Policy
• Hanmi launches Zytiga generic combo after first generic
• by Lee, Tak-Sun Feb 16, 2024 06:00am

• Policy
• MFDS will inspect growth hormones and cold chains this year
• by Lee, Hye-Kyung Feb 16, 2024 05:59am

• Policy
• ‘Trelegy 200 Ellipta’ concludes negotiations with the NHIS
• by Lee, Tak-Sun Feb 15, 2024 05:59am

• Policy
• The guidelines for PVA will be revised soon
• by Lee, Tak-Sun Feb 15, 2024 05:58am

• Policy
• Price cut hold for Forxiga, Xigduo, Atmeg Combi are extended
• by Lee, Jeong-Hwan Feb 14, 2024 05:40am

• Policy
• Chinese MM drug Xpovio reattempts reimb listing in KOR
• by Lee, Tak-Sun Feb 14, 2024 05:40am